Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals

Abstract

CAR-NK cell therapy does not require HLA matching and has minimal side effects. However, traditional methods of engineering CARs into human tissue-derived NK cells exhibit heterogeneity, low transduction efficiency, and high manufacturing costs. Here, we provide a reliable approach for generating large-scale and cryopreserved mesothelin (MSLN) CAR-NK cells from human embryonic stem cells (hESCs) as an alternative cell source. We first constructed MSLN CAR-expressing hESCs to reduce CAR engineering costs and subsequently differentiated these stem cells into MSLN CAR-NK cells via an efficient organoid induction system. The MSLN CAR-NK cells exhibit the typical expression patterns of activating receptors, inhibitory receptors, and effector molecules of NK cells. In the presence of tumour cells, the MSLN CAR-NK cells show increased secretion of IFN-γ and TNF-α, as well as elevated CD107a expression level compared with induced NK cells. We cryopreserved the MSLN CAR-NK cells in liquid nitrogen using a clinical-grade freezing medium (CS10) for more than 6 months to mimic an off-the-shelf CAR-NK cell product. The thawed MSLN CAR-NK cells immediately recovered after 48–72-h culture and effectively eliminated ovarian tumour cells, including human primary ovarian tumour cells from patients. The thawed MSLN CAR-NK cells efficiently suppressed ovarian tumour development in vivo and prolonged the survival of tumour-bearing mice. Our study provides insights into the clinical translation of hESC-derived MSLN CAR-NK cells as a promising off-the-shelf cell product.

References

[1] VivierE, Rebuffet L, Narni-MancinelliE, CornenS, Igarashi RY, FantinVR. Natural killer cell therapies. Nature. 2024; 626(8000):727-736.

[2] SrivastavaS, Lundqvist A, ChildsRW. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy. 2008; 10(8):775-783.

[3] PageA, ChuvinN, Valladeau-GuilemondJ, DepilS. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024; 21(4):315-331.

[4] ChuJ, GaoF, YanM, et al. Natural killer cells: a promising immunotherapy for cancer. J Transl Med. 2022; 20(1):240.

[5] MarinD, LiY, BasarR, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial. Nat Med. 2024; 30(3):772-784.

[6] KongJC, Sa’ad MA, VijayanHM, et al. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Front Immunol. 2024; 15:1384039.

[7] HeipertzEL, ZyndaER, Stav-NoraasTE, et al. Current perspectives on "off-the-shelf" allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021; 12:732135.

[8] LiY, Hermanson DL, MoriarityBS, KaufmanDS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018; 23(2):181-192 e185.

[9] WoanKV, KimH, BjordahlR, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell. 2021; 28(12):2062-2075 e2065.

[10] CichockiF, Goodridge JP, BjordahlR, et al. Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 2022; 140(23):2451-2462.

[11] EbrahimiyanH, TamimiA, ShokoohianB, et al. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Int Immunopharmacol. 2022; 106:108587.

[12] WangW, LiuY, HeZ, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024; 10(1):40.

[13] MaalejKM, MerhiM, InchakalodyVP, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023; 22(1):20.

[14] MorelloA, Sadelain M, AdusumilliPS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016; 6(2):133-146.

[15] HaasAR, TanyiJL, O’HaraMH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019; 27(11):1919-1929.

[16] ChenJ, HuJ, GuL, et al. Correction to: anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023; 72(10):3401-3403.

[17] ChowdhuryPS, VinerJL, BeersR, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA. 1998; 95(2):669-674.

[18] RivellaS, Callegari JA, MayC, TanCW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol. 2000; 74(10):4679-4687.

[19] HuangD, LiJ, HuF, et al. Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells. Cell Discov. 2022; 8(1):121.

[20] WangY, LiJ, WangZ, et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif. 2024;e13683.

[21] DingS, WuX, LiG, HanM, ZhuangY, Xu T. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell. 2005; 122(3):473-483.

[22] WuP, WeiH, ZhangC, Zhang J, TianZ. Regulation of NK cell activation by stimulatory and inhibitory receptors in tumor escape from innate immunity. Front Biosci. 2005; 10:3132-3142.

[23] ZamaiL, AhmadM, BennettIM, Azzoni L, AlnemriES, PerussiaB. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998; 188(12):2375-2380.

[24] HuntingtonND, Vosshenrich CA, Di SantoJP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007; 7(9):703-714.

[25] NiF, SunR, FuB, et al. IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat Commun. 2013; 4:1479.

[26] HuangY, ZengJ, LiuT, XuQ, SongX, Zeng J. DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular cancer cells in vitro. Cancer Manag Res. 2020; 12:3247-3255.

[27] SanberK, SavaniB, JainT. Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021; 195(5):660-668.

[28] SchubertML, Schmitt M, WangL, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021; 32(1):34-48.

[29] ZhangY, QinD, ShouAC, Liu Y, WangY, ZhouL. Exploring CAR-T cell therapy side effects: mechanisms and management strategies. J Clin Med. 2023; 12(19):6124.

[30] LevineBL, Pasquini MC, ConnollyJE, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024; 30(2):338-341.

[31] MarkC, Czerwinski T, RoessnerS, et al. Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells. Nat Commun. 2020; 11(1):5224.

RIGHTS & PERMISSIONS

2024 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.